ライフサイエンスコーパス: ERAS

1 ERAS and Pain Management CPGs were developed by a multid

2 ERAS in principle seems logical and safe for esophagecto

3 ERAS programs include perioperative interventions that w

4 ERAS programs use multimodal approaches to reduce compli

5 S of 4.4 d (95% CI: -6.8, -2.0 d; P < 0.001).ERAS patients consumed more protein due to the inclusion

6 tial barriers and enablers to adoption of 18 ERAS interventions.

7 erence-in-differences study before and after ERAS implementation in the target populations compared w

8 Although ERAS is well established in colorectal surgery, experien

9 on rates were also significantly lower among ERAS target populations after implementation.

10 eam consisting of surgeons, anesthetists, an ERAS coordinator (often a nurse or a physician assistant

11 ) cycle was used to develop and implement an ERAS CPG at 15 academic hospitals in Canada.

12 cle can be used to successfully implement an ERAS program at multiple sites.

13 rst step toward successfully implementing an ERAS program.

14 If patients were managed in an ERAS pathway, the only significant reductions were in in

15 al surgery, particularly those managed in an ERAS setting.

16 Implementation included development of an ERAS guideline by a multidisciplinary group, communities

17 Multicenter implementation of an ERAS program among patients undergoing elective colorect

18 ive staff supported the implementation of an ERAS program at the University of Toronto-affiliated hos

19 t of patients, increasing compliance with an ERAS program and the use of laparoscopic surgery indepen

20 ion patients after conventional (n = 46) and ERAS (n = 69) care.

21 Six retrospective studies have assessed ERAS for esophagectomy, demonstrating favorable morbidit

22 ltimodal analgesia approach for a colorectal ERAS pathway, most patients used less opioids while in t

23 Consequently, ERAS may have a significant role to play in improving ou

24 n and collaboration, and better evidence for ERAS interventions.

25 ta strongly indicate that in quiescent HSCs, ERAS targets AKT via two distinct pathways driven by PI3

26 eams from hospitals are trained to implement ERAS processes.

27 iety that promotes, develops, and implements ERAS programs, publishes updated guidelines for many ope

28 Increasing ERAS compliance was correlated with fewer complications

29 Local ERAS teams from hospitals are trained to implement ERAS

30 ements in clinical outcomes and cost, making ERAS an important example of value-based care applied to

31 The international, multicenter ERAS registry data, collected between November 2008 and

32 -scale implementation of a multidisciplinary ERAS program is feasible and effective in improving surg

33 A multifaceted ERAS program designed with a particular focus on periope

34 Despite the known benefits of ERAS programs, uptake remains slow.

35 is little direct evidence for components of ERAS, with much derived from nonesophageal thoracoabdomi

36 literature was searched for descriptions of ERAS in esophagectomy.

37 Expression of ERAS in human melanoma cell lines conferred resistance t

38 mothripsis and leading to high expression of ERAS, a constitutively active RAS protein normally expre

39 Implementation of ERAS programs results in major improvements in clinical

40 otably, in quiescent HSCs, the high level of ERAS protein correlates with the activation of AKT, STAT

41 can therefore not be recommended as part of ERAS pathways in laparoscopic colorectal surgery.

42 Thus, in contrast to the reported role of ERAS in tumor cells associated with cell proliferation,

43 Prospective study of ERAS program, a multidisciplinary effort involving anest

44 the enhanced recovery after surgery pathway (ERAS) has emerged as one of the best strategies to impro

45 , disease characteristics, and perioperative ERAS protocol compliance were assessed.

46 port that embryonic stem cell-expressed RAS (ERAS) is specifically expressed in quiescent HSCs and do

47 of hospital stay (LOS) in patients receiving ERAS protocols and conventional care.We conducted a pros

48 ng patients undergoing colorectal resection, ERAS implementation was associated with decreased rates

49 pportive of implementation of a standardized ERAS program and agreed that a standardized guideline ba

50 7 patients recruited for the Early RA Study (ERAS), a multicenter, inception cohort study with follow

51 Components of successful ERAS programs were determined, and when not directly ava

52 Enhanced recovery after surgery (ERAS) colorectal programs have shown to be successful at

53 Enhanced Recovery After Surgery (ERAS) is a paradigm shift in perioperative care, resulti

54 comes of an enhanced recovery after surgery (ERAS) program among 2 target populations: patients under

55 ption of an Enhanced Recovery after Surgery (ERAS) program by the multidisciplinary perioperative tea

56 c review of enhanced recovery after surgery (ERAS) programs for esophagectomy and generate guidelines

57 Enhanced Recovery After Surgery (ERAS) protocols are evidence-based care bundles that red

58 Enhanced Recovery After Surgery (ERAS) protocols have been shown to increase recovery, de

59 y pathways [enhanced recovery after surgery (ERAS)].

60 ll proliferation, our findings indicate that ERAS is important to maintain quiescence in HSCs.

61 We show that ERAS expression elicits a prosurvival signal associated

62 The ERAS (enhanced recovery after surgery) care has been sho

63 The ERAS group had shorter LOS (P = 0.049) and fewer total i

64 The ERAS Society conducts structured implementation programs

65 The ERAS Society, an international nonprofit professional so

66 ein intakes were significantly higher in the ERAS group due to the inclusion of oral nutrition supple

67 ics had significantly greater changes in the ERAS target populations after implementation compared wi

68 ch for patients both using and not using the ERAS pathway to reduce opioid consumption.

69 resection cases performed in 2009 (prior to ERAS implementation), 2011, and 2012.

70 We also found a novel fusion involving USP9X-ERAS formed by chromothripsis and leading to high expres

71 This USP9X-ERAS fusion appeared highly oncogenic on the basis of it